Close Menu

Oxford BioDynamics

The firm's EpiSwitch test for blood-based diagnosis of prostate cancer will be evaluated as part of the ongoing PROSTAGRAM trial.

The company, which went public in 2017, generates all its revenues through its epigenetic biomarker research and development partnerships.

Oxford BioDynamics will work with Italian research institute Casa Sollievo della Sofferenza to identify blood-based biomarkers of autism spectrum disorder.

Participants aim to use predictive modeling to better understand epigenetic mechanisms, while encouraging the development of new technologies and therapies.

Oxford BioDynamics has developed a platform for discovering, evaluating, validating, and monitoring a unique class of epigenetic biomarkers.

The effort, which relied on Oxford BioDynamics' EpiSwitch platform, resulted in an assay that researchers believe could be developed into a test to guide therapy selection for patients.

The partners will perform blood-based tests on Oxford's Episwitch platform to monitor epigenetic changes of athletes with concussions.

The British company has announced the results of two studies showcasing the ability of its EpiSwitch platform to diagnose and stage breast cancer and ALS patients.

Nova Satra said it will use the EpiSwitch technology to develop and commercialize non-invasive breast cancer testing across 13 territories in Asia.

Bloomberg reports that the DNA-for-cash deal reported in Kentucky might be a more widespread scam.

St. Jude Children's Research Hospital scientists have treated infants with X-linked severe combined immunodeficiency using gene therapy in an early phase study.

St. Louis Public Radio reports that some African Americans are turning to DNA ancestry testing to help guide genealogical searches.

In Nature this week: a genomic analysis of the snailfish Pseudoliparis swirei, ancient DNA analysis gives insight into the introduction of farming to England, and more.